The prognostic significance of c-erbB-2 oncoprotein in lung carcinomas

October 6, 2011

The prognostic significance of c-erbB-2 oncoprotein in lung carcinomas

This is an automatically generated default intro template – please do not edit.

General information
Title:	The prognostic significance of c-erbB-2 oncoprotein in lung carcinomas
Meta keywords:
Meta description:
Images information
Images path absolute:	/home/studia/public_html/v15/images/stories/com_form2content/p3/f110
Images path relative:	com_form2content/p3/f110
Thumbs path absolute:
Thumbs path relative:
Fields information
Article_Title:	The prognostic significance of c-erbB-2 oncoprotein in lung carcinomas
Authors:	Mirela Grigoraş, Elena Lazăr, Alis Dema, Marioara Cornianu, Anca Mureşan, Codruţa Lăzureanu, Alexandra Faur
Affiliation:	Department of Pathology, University of Medicine and Pharmacy “Victor Babeş” Timişoara, Romania
Abstract:	We assessed the immunohistochemical expression of c-erbB-2 transmembrane receptor in 15 primary lung carcinomas using the polyclonal antibody anti-human c-erbB-2 oncoprotein. Tissue fragments routinely processed (formalin-fixed and paraffin-embedded) were then investigated for c-erbB-2 oncoprotein expression using the Avidin-Biotin Complex staining method. Tumor cells showed positive c-erbB-2 expression in 86.6% of non small cell lung carcinomas (NSCLC). Positive c-erbB-2 immunoreaction correlated with the advanced stage of the disease, with lymph node involvement and high metastasis rate. The results obtained suggest that tissue overexpression of c-erbB-2 protein in NSCLC characterizes a group of tumors with an aggressive clinical-biological behavior and poor prognosis; c-erbB-2 protein can be considered a useful tumor marker in the morphological diagnosis and monitoring the clinical behavior of these neoplasms.
Keywords:	lung carcinomas, immunohistochemistry, c-erbB-2 oncoprotein
References:	Hirsch FR, Franklin WA, Veve R, Varella-Garcia M, Bunn PA Jr. HER2/neu expression in malignant lung tumors. Semin Oncol 2002; 29: 51-58. Harris JR, Lippman ME, Morrow M, Hellman S. Diseases of the breast. Lippincot-Raven Publishers, Philadelphia, 1996. McCann A, Dervan PA, Johnston PA, Gullick WJ, Carney DN. C-erbB-2 oncoprotein expression in primary human tumors. Cancer 1990; 65: 88-92. Kuniyuki O, Takashi N, Tatsuo A. C-erbB-2 oncoprotein expression is associated with poor prognosis in squamous cell carcinoma of the cervix. Cancer 1994; 73: 668-671. Toshihiro O, Titsuya N, Tsunehiro O, Ryoichi N, Kosei Y. Serum level and tissue expression of C-erbB-2 protein in lung adenocarcinoma. Chest 1995; 108:157-162. Toshimasa K, Hitoshi T, Shinichi T, Kiyoaki N et al. Prognostic significance of the overexpression of c-erbB-2 protein in adenocarcinoma of the uterine cervix. Cancer 1994; 73: 148-153. Meden H, Marx D, Rath M, Kron A, Fattahi-Neibodi A, Hinney B et al. Overexpression of the oncogene c-erbB-2 in primary ovarian cancer: evaluation of the prognostic value in a cox proportional hazards multiple regression. Int J Gynecol Pathol 1994; 13:45-53. Yokoto J, Yamamoto T, Toyoshima K et al. Amplification of c-erbB-2 oncogene in human adenocarcinomas in vivo. Lancet 1986; 1: 765-766. Meert AP, Martin B, Paesmans M, Berghmans T, Mascaux C et al. The role of HER-2/neu expression on the survival of patients with lung cancer: a systematic review of the literature. Br J Cancer 2003; 89: 959-965. Tal M, Weltzer M, Josefberg Z et al. Sporadic amplification of the Her 2/neu protooncogene in adenocarcinomas of various tissues. Cancer Res 1988; 48: 1517-1520. Cheng CM, Tsuneyama K, Matsui K, Takanashi H, Ishizawa S, Takano Y. Cytoplasmic expression of c-erbB-2 in non-small cell lung cancers. Virchows Arch 2005; 446: 596-603. Cornianu M, Tudose N. Aportul markerilor imunohistochimici in diagnosticul morphologic al carcinoamelor pulmonare. Zilele Academice Timisorene 24-25 mai 1997. Lucrare publicata in volumul de rezumate. Coombs LM, Oliver S, Sweeney E, Knowles M. Immunohistochemical localization of c-erbB-2 in transitional cell carcinoma of the urinary bladder. J Pathol 1993; 169: 35-42. De Potter CR, Quataker J, Maerteus G et al. The subcellular localization of the neu protein in human normal and neoplastic cells. Int J Cancer 1989; 44:969-974.
Read_full_article:	pdf/21-2011/21-3-2011/SU21-3-2011-Grigoras.pdf
Correspondence:

	Read full article
Article Title:	The prognostic significance of c-erbB-2 oncoprotein in lung carcinomas
Authors:	Mirela Grigoraş, Elena Lazăr, Alis Dema, Marioara Cornianu, Anca Mureşan, Codruţa Lăzureanu, Alexandra Faur
Affiliation:	Department of Pathology, University of Medicine and Pharmacy “Victor Babeş” Timişoara, Romania
Abstract:	We assessed the immunohistochemical expression of c-erbB-2 transmembrane receptor in 15 primary lung carcinomas using the polyclonal antibody anti-human c-erbB-2 oncoprotein. Tissue fragments routinely processed (formalin-fixed and paraffin-embedded) were then investigated for c-erbB-2 oncoprotein expression using the Avidin-Biotin Complex staining method. Tumor cells showed positive c-erbB-2 expression in 86.6% of non small cell lung carcinomas (NSCLC). Positive c-erbB-2 immunoreaction correlated with the advanced stage of the disease, with lymph node involvement and high metastasis rate. The results obtained suggest that tissue overexpression of c-erbB-2 protein in NSCLC characterizes a group of tumors with an aggressive clinical-biological behavior and poor prognosis; c-erbB-2 protein can be considered a useful tumor marker in the morphological diagnosis and monitoring the clinical behavior of these neoplasms.
Keywords:	lung carcinomas, immunohistochemistry, c-erbB-2 oncoprotein
References:	Hirsch FR, Franklin WA, Veve R, Varella-Garcia M, Bunn PA Jr. HER2/neu expression in malignant lung tumors. Semin Oncol 2002; 29: 51-58. Harris JR, Lippman ME, Morrow M, Hellman S. Diseases of the breast. Lippincot-Raven Publishers, Philadelphia, 1996. McCann A, Dervan PA, Johnston PA, Gullick WJ, Carney DN. C-erbB-2 oncoprotein expression in primary human tumors. Cancer 1990; 65: 88-92. Kuniyuki O, Takashi N, Tatsuo A. C-erbB-2 oncoprotein expression is associated with poor prognosis in squamous cell carcinoma of the cervix. Cancer 1994; 73: 668-671. Toshihiro O, Titsuya N, Tsunehiro O, Ryoichi N, Kosei Y. Serum level and tissue expression of C-erbB-2 protein in lung adenocarcinoma. Chest 1995; 108:157-162. Toshimasa K, Hitoshi T, Shinichi T, Kiyoaki N et al. Prognostic significance of the overexpression of c-erbB-2 protein in adenocarcinoma of the uterine cervix. Cancer 1994; 73: 148-153. Meden H, Marx D, Rath M, Kron A, Fattahi-Neibodi A, Hinney B et al. Overexpression of the oncogene c-erbB-2 in primary ovarian cancer: evaluation of the prognostic value in a cox proportional hazards multiple regression. Int J Gynecol Pathol 1994; 13:45-53. Yokoto J, Yamamoto T, Toyoshima K et al. Amplification of c-erbB-2 oncogene in human adenocarcinomas in vivo. Lancet 1986; 1: 765-766. Meert AP, Martin B, Paesmans M, Berghmans T, Mascaux C et al. The role of HER-2/neu expression on the survival of patients with lung cancer: a systematic review of the literature. Br J Cancer 2003; 89: 959-965. Tal M, Weltzer M, Josefberg Z et al. Sporadic amplification of the Her 2/neu protooncogene in adenocarcinomas of various tissues. Cancer Res 1988; 48: 1517-1520. Cheng CM, Tsuneyama K, Matsui K, Takanashi H, Ishizawa S, Takano Y. Cytoplasmic expression of c-erbB-2 in non-small cell lung cancers. Virchows Arch 2005; 446: 596-603. Cornianu M, Tudose N. Aportul markerilor imunohistochimici in diagnosticul morphologic al carcinoamelor pulmonare. Zilele Academice Timisorene 24-25 mai 1997. Lucrare publicata in volumul de rezumate. Coombs LM, Oliver S, Sweeney E, Knowles M. Immunohistochemical localization of c-erbB-2 in transitional cell carcinoma of the urinary bladder. J Pathol 1993; 169: 35-42. De Potter CR, Quataker J, Maerteus G et al. The subcellular localization of the neu protein in human normal and neoplastic cells. Int J Cancer 1989; 44:969-974.
*Correspondence:

About The Author

dti